In February 2018 the U.S. Food and Drug Administration (FDA) made a giant leap in modernizing its approach to its evaluation for new drugs for Alzheimer’s disease and other neurologic disease. This is welcome news to researchers who are searching for medications to treat these conditions. For many years, the standard for a new drug for Alzheimer’s disease has focused on generating evidence that...
News
The Importance of Biomarkers in Diagnosing Alzheimer’s Disease
Back in July we reported that the Bill Gates had launched a new fund to support Alzheimer’s research called Diagnostic Accelerator. The project is a part of the Alzheimer’s Drug Discovery Foundation (ADDF) aims to accelerate bold new ideas for earlier and better diagnosis of the disease. This is important for will contests, since an accurate diagnosis sometimes forms the basis of litigation in challenging a will.
New Study Links Connection Between Stroke and Dementia
A study recently conducted by The University of Exeter Medical School analyzed the data on stroke and dementia risk from 3.2 million individuals around the world. The data revealed that the link between stroke and dementia persisted even after taking into effect factors such as blood pressure, diabetes and cardiovascular disease. These findings from the largest study of its kind provide the...
BREAKING NEWS: Zombie Cells Identified for First Time in Alzheimer’s Disease
The team found that the stress, called cellular senescence, is associated with harmful tau
protein tangles that are a hallmark of 20 human brain diseases, including Alzheimer’s
and traumatic brain injury. The researchers identified senescent cells in postmortem
brain tissue from Alzheimer’s patients and then found them in postmortem tissue from
another brain disease, progressive supranuclear palsy.
Understanding the Seven Stages of Alzheimer’s Disease
It is well known that Alzheimer’s is a progressive disease, advancing through distinct stages of decline. Every individual will experience the disease differently, but the trajectory of the disease from the beginning to the end is often similar. On average, a person lives for four to eight years after diagnosis. However, changes in the brain related to the disease begin years before any...
U.S. Government Ramps Up Alzheimer’s Research
On August 23rd the U.S. Senate voted to pass the largest increase in history earmarked for Alzheimer’s Research. The increase of $425 million would go to Alzheimer’s and dementia research funding at the National Institutes of Health. This funding would bring the country’s total investment to $2.34 billion for fiscal year 2019. If signed into law, this would mark the fourth year in a row that the...